ArticleEClinicalMedicine2024

Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial.

Shuxiang Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.